Poster
AcceleRET Lung: a phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC
Author
Sanjay Popat
Condition
RET fusion–positive advanced/metastatic NSCLC
Drug target
RET fusions
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-ASCO-2022-Pralsetinib-AcceleRET-Lung-Poster.pdf
16 organizations
1 product
Product
PralsetinibOrganization
The Royal Marsden HospitalOrganization
City of Hope National Medical CenterOrganization
Yonsei University College of MedicineOrganization
Netherlands Cancer InstituteOrganization
IRCCS Giovanni - Paolo II Istituto OncologicoOrganization
IRCCS Ospedale San RaffaeleOrganization
University Hospital of ZürichOrganization
Genentech Inc.Organization
Vall d’Hebron University Hospital/VHIOOrganization
European Institute of OncologyOrganization
University Hospital Carl Gustav CarusOrganization
Fondazione IRCCS - Istituto Nazionale dei TumoriOrganization
Asan Medical CenterOrganization
Instituto Português de Oncologia – PortoOrganization
F. Hoffmann-La Roche, Ltd.Organization
Institut Gustave Roussy